<SEC-DOCUMENT>0001104659-25-010636.txt : 20250207
<SEC-HEADER>0001104659-25-010636.hdr.sgml : 20250207
<ACCEPTANCE-DATETIME>20250207192118
ACCESSION NUMBER:		0001104659-25-010636
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250207
DATE AS OF CHANGE:		20250207

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amphastar Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001297184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330702205
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88204
		FILM NUMBER:		25603266

	BUSINESS ADDRESS:	
		STREET 1:		11570 SIXTH STREET
		CITY:			RANCHO CUCAMONGA
		STATE:			CA
		ZIP:			91730
		BUSINESS PHONE:		909-980-9484

	MAIL ADDRESS:	
		STREET 1:		11570 SIXTH STREET
		CITY:			RANCHO CUCAMONGA
		STATE:			CA
		ZIP:			91730

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zhang Jack Y.
		CENTRAL INDEX KEY:			0001611157
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		11570 6TH STREET
		CITY:			RANCHO CUCAMONGA
		STATE:			CA
		ZIP:			91730
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-15-009569</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Zhang Jack Y. -->
          <cik>0001611157</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>10</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001297184</issuerCik>
        <issuerName>Amphastar Pharmaceuticals, Inc.</issuerName>
        <issuerCusip>03209R103</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>11570 SIXTH STREET</com:street1>
          <com:city>Rancho Cucamonga</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>91730</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Jack Y. Zhang</reportingPersonName>
      <citizenshipOrOrganization>F4</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3899921.00</soleVotingPower>
        <sharedVotingPower>8624232.00</sharedVotingPower>
        <soleDispositivePower>3899921.00</soleDispositivePower>
        <sharedDispositivePower>8624232.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>12524153.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>24.8</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The shares set forth in Row 9 include (i) 2,312,948 shares of common stock held of record by Jack Y. Zhang; (ii) 1,586,973 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2024 by Dr. Zhang; (iii) 1,021,492 shares of common stock held of record by Mary Z. Luo, Dr. Zhang's spouse; (iv) 775,061 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2024 by Dr. Luo; and (v) 6,827,679 shares of common stock held of record by Applied Physics &amp; Chemistry Laboratories, Inc., or APCL, of which Dr. Zhang, Dr. Luo and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.

The percentage set forth in Row 11 is based on 48,081,433 shares of the Issuer's common stock outstanding as of November 1, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 7, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Mary Z. Luo</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>1796553.00</soleVotingPower>
        <sharedVotingPower>10727600.00</sharedVotingPower>
        <soleDispositivePower>1796553.00</soleDispositivePower>
        <sharedDispositivePower>10727600.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>12524153.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>24.8</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The shares set forth in Row 9 include (i) 1,021,492 shares of common stock held of record by Mary Z. Luo; (ii) 775,061 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2024 by Dr. Luo; (iii) 2,312,948 shares of common stock held of record by Jack Y. Zhang, Dr. Luo's spouse; (iv) 1,586,973 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2024 by Dr. Zhang; and (v) 6,827,679 shares of common stock held of record by Applied Physics &amp; Chemistry Laboratories, Inc., or APCL, of which Dr. Luo, Dr. Zhang and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.

The percentage set forth in Row 11 is based on 48,081,433 shares of the Issuer's common stock outstanding as of November 1, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 7, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Applied Physics &amp; Chemistry Laboratories, Inc.</reportingPersonName>
      <citizenshipOrOrganization>CA</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>6827679.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>6827679.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6827679.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>14.2</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>Jack Y. Zhang, Mary Z. Luo and The Bill Luobei Zhang 2004 Irrevocable Trust, the sole owners of Applied Physics &amp; Chemistry Laboratories, Inc., or APCL, have shared voting and dispositive power over the shares set forth in Row 9.

The percentage set forth in Row 11 is based on 48,081,433 shares of the Issuer's common stock outstanding as of November 1, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 7, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Amphastar Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>11570 6th Street Rancho Cucamonga, CA, 91730</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Jack Y. Zhang
Mary Z. Luo
Applied Physics &amp; Chemistry Laboratories, Inc.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The address for the principal business office of Dr. Zhang and Dr. Luo is:

c/o Amphastar Pharmaceuticals, Inc.
11570 6th Street
Rancho Cucamonga, California 91730

The address for the principal business office of APCL is:

13760 Magnolia Avenue
Chino, California 91710</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Reference is hereby made to the response to item 4 on each of pages 2-4 of this Schedule 13G (this "Schedule"), which responses are incorporated herein by reference.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Reference is hereby made to the responses to items 5-9 of each of pages 2-4 of this Schedule, which responses are incorporated herein by reference.</amountBeneficiallyOwned>
        <classPercent>Reference is hereby made to the response to item 11 on each of pages 2-4 of this Schedule, which responses are incorporated herein by reference.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Reference is hereby made to the response to item 5 on each of pages 2-4 of this Schedule, which responses are incorporated herein by reference.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Reference is hereby made to the response to item 6 on each of pages 2-4 of this Schedule, which responses are incorporated herein by reference.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Reference is hereby made to the response to item 7 on each of pages 2-4 of this Schedule, which responses are incorporated herein by reference.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Reference is hereby made to the response to item 8 on each of pages 2-4 of this Schedule, which responses are incorporated herein by reference.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <exhibitInfo>Exhibit 99.1 Joint Filing Agreement, dated February 5, 2015, by and among Jack Yongfeng Zhang, Mary Ziping Luo and Applied Physics &amp; Chemistry Laboratories, Inc. https://www.sec.gov/Archives/edgar/data/1297184/000110465915009569/a15-4133_1ex99d1.htm filed with the SEC as Exhibit 99.1 to the Schedule 13G on February 12, 2015.</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Jack Y. Zhang</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Jack Y. Zhang</signature>
        <title>Jack Y. Zhang</title>
        <date>02/07/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Mary Z. Luo</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Mary Z. Luo</signature>
        <title>Mary Z. Luo</title>
        <date>02/07/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Applied Physics &amp; Chemistry Laboratories, Inc.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Jack Y. Zhang</signature>
        <title>Jack Y. Zhang, President</title>
        <date>02/07/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
